GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Natus Medical Inc (NAS:NTUS) » Definitions » EV-to-EBITDA

Natus Medical (Natus Medical) EV-to-EBITDA : 21.87 (As of May. 11, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Natus Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Natus Medical's enterprise value is $1,065.8 Mil. Natus Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $48.7 Mil. Therefore, Natus Medical's EV-to-EBITDA for today is 21.87.

The historical rank and industry rank for Natus Medical's EV-to-EBITDA or its related term are showing as below:

NTUS's EV-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.47
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Natus Medical's stock price is $32.96. Natus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.370. Therefore, Natus Medical's PE Ratio for today is 89.08.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Natus Medical EV-to-EBITDA Historical Data

The historical data trend for Natus Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natus Medical EV-to-EBITDA Chart

Natus Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.00 142.73 78.89 68.98 15.17

Natus Medical Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.83 23.36 15.09 15.17 17.12

Competitive Comparison of Natus Medical's EV-to-EBITDA

For the Medical Devices subindustry, Natus Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natus Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Natus Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Natus Medical's EV-to-EBITDA falls into.



Natus Medical EV-to-EBITDA Calculation

Natus Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1065.804/48.743
=21.87

Natus Medical's current Enterprise Value is $1,065.8 Mil.
Natus Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Natus Medical  (NAS:NTUS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Natus Medical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=32.96/0.370
=89.08

Natus Medical's share price for today is $32.96.
Natus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.370.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Natus Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Natus Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Natus Medical (Natus Medical) Business Description

Traded in Other Exchanges
N/A
Address
3150 Pleasant View Road, Middleton, WI, USA, 53562
Natus Medical Inc is a provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. It is divided into three business units: Neuro, Newborn Care, and Hearing and Balance. The company generates a majority of its revenue from the Neurology business unit which includes products and services that provide diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care, and neurosurgery.
Executives
Chung Dong Chune Christopher officer: Vice President Medical Affairs 1501 INDUSTRIAL ROAD SAN CARLOS CA 94070
Bryant M Moore director 181 HARVEST LANE PITTSBORO NC 27312
Eric Guerin director 1950 HASSELL ROAD, HOFFMAN ESTATES IL 60169
Ilan Daskal director 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice D. Schroeder director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Jonathan Kennedy director, officer: Sr. VP, CFO INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Ken Ludlum director
Robert A Gunst director
Noll Austin Francis Iii officer: VP/GM Neurology 9805 FALLEN LEAF DRIVE MIDDLETON WI 53562
Thomas Joseph Sullivan director 64 PETTIT PL PRINCETON NJ 08540
Benjamin Drew Davies officer: Sr. VP, CFO 1501 INDUSTRIAL ROAD, SAN CARLOS X1 94070
Joshua Levine director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sharon Villaverde officer: Interim CFO 11780 U.S. HIGHWAY 1, SUITE 600, PALM BEACH GARDENS FL 33408
William M Moore director